Olaparib AZD-2281 CAS 763113-22-0 Purity ≥99.0% API Factory
Bohloeki bo Phahameng, Tlhahiso ea Khoebo
Olaparib le Li-intermediate tse Amanang le tsona:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid CAS 763114-26-7
1-(Cyclopropylcarbonyl)piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Lebitso la Lik'hemik'hale | Olaparib |
| Litlhaloso tse tšoanang | AZD-2281;KU0059436;Lynparza;4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one;1-(Cyclopropylcarbonyl) -4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)Methyl]-2-fluorobenzoyl]piperazin |
| Nomoro ea CAS | 763113-22-0 |
| Nomoro ea KAtse | RF-API103 |
| Boemo ba Setoko | Ka Setokong, Phatlalatso e Eketsehile ho fihla ho Makholo a Lik'hilograma |
| Foromo ea limolek'hule | Setšoantšo sa C24H23FN4O3 |
| Boima ba Molek'hule | 434.46 |
| Solubility | E qhibiliha ka DMSO |
| Brand | Ruifu Chemical |
| Ntho | Litlhaloso |
| Ponahalo | Phofo e tšoeu ho isa ho e tšoeu |
| Boitsebiso ka 1H NMR | Lumellana le sebopeho |
| LC-MS | Lumellana le sebopeho |
| Mokhoa oa Bohloeki / Analysis | ≥99.0% (ka LC-MS) |
| Mongobo (KF) | ≤0.50% |
| Tšilafalo e le Mong | ≤0.50% |
| Litšila ka Kakaretso | ≤1.0% |
| Heavy Metals (as Pb) | ≤20ppm |
| Tekanyetso ea Teko | Maemo a Khoebo |
| Tšebeliso | API;PARP Inhibitor |
Sephutheloana: Botlolo, Aluminium foil bag, Cardboard Drum, 25kg/Drum, kapa ho latela tlhoko ea moreki.
Boemo ba polokelo:Boloka ka lijaneng tse koetsoeng sebakeng se phodileng le se omileng;Sireletsa leseli le mongobo.
Olaparib (CAS: 763113-22-0), e matla haholo ebile e khetha PARP-inhibitor.Ka la 19 Tšitoe, 2014, FDA e amohetse sethethefatsi se khahlanong le mofetše Olaparib (Lynparza) bakeng sa monotherapy ho bakuli ba mofets'e o tsoetseng pele oa mahe a bomme ba kileng ba etsa chemotherapy ka makhetlo a 3 kapa bakuli bao ho belaelloang hore ke liphetoho tsa BRCA.Ka nako e ts'oanang, FDA e amohetse palo le lihlopha tsa lisebelisoa tsa tlhahlobo bakeng sa ho lemoha liphetoho tse teng ho BRCA1 le BRCA2, BRCAanalysis CDx.Olaparib ke lithethefatsi tsa pele tsa PARP inhibitor tse amohetsoeng ke FDA.Ka la 2 Hlakola 2015, European Union Food and Drug Administration (EMA) le eona e amohetse Olaparib ho kena 'marakeng linaheng tse 28 tsa European Union ho kenyeletsoa Iceland, Liechtenstein le Norway.Empa lipontšo tsa EMA le FDA tse amohetsoeng li fapane hanyane;ea pele ke ea linyeoe tsa phetoho ea liphatsa tsa lefutso tsa BRCA, hape ke tsa kalafo ea tlhokomelo bakeng sa bakuli ba mofetše o tsoetseng pele oa epithelial ovarian bao pele ba kileng ba fumana litlhare tsa chemotherapy tse nang le platinum mme ba bonts'a karabelo le ho ipheta hape.
